查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604757

自体免疫疾病治疗药物市场：按产品、应用分类 - 全球预测 2025-2030

Autoimmune Disease Therapeutics Market by Product (Diagnostic Equipment, Drugs), Application (Localized Autoimmune Diseases, Systemic Autoimmune Diseases) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，自体免疫疾病治疗市值为1,989.9亿美元，预计2024年将达到2,145.4亿美元，复合年增长率为7.90%，到2030年将达到3,390亿美元。

自体免疫疾病治疗市场包括旨在管理和减轻自体免疫疾病的治疗方法和药物，在这种疾病中，人体的免疫系统错误地攻击自身组织。类风湿性关节炎、狼疮和多发性硬化症等自体免疫疾病的日益流行推动了对这些疗法的需求，这些疾病需要复杂的医疗干预措施。这些疗法的用途包括生物製药、免疫抑制剂和单株抗体，它们针对免疫系统的特定成分来缓解症状并改善患者的治疗结果。最终用途包括专门治疗自体免疫疾病的医院、诊所和专科中心。

主要市场统计
基准年[2023] 1989.9亿美元
预计年份 [2024] 2145.4亿美元
预测年份 [2030] 3390亿美元
复合年增长率（%） 7.90%

影响该市场的主要成长要素包括生物技术的进步、对自体免疫疾病的认识不断提高以及新疗法研发投资的增加。个人化医疗的兴起也推动了成长，因为治疗方法可以根据个人的基因特征进行客製化。新兴市场存在着机会，医疗基础设施得到改善，对可近治疗方法的需求不断增长。製药公司和研究机构之间的合作研究可以带来突破性的治疗方法。公司必须专注于提高药物的功效和安全性，以获得市场占有率。

然而，挑战仍然存在，包括高昂的治疗成本、严格的法律规范以及与长期使用相关的潜在副作用。此外，对疾病机制的了解有限也阻碍了突破。创新应集中在基因治疗和开发更精确、副作用更少的生技药品。远端医疗位治疗等数位健康解决方案可以改善患者监测和治疗依从性。

总体而言，市场充满活力，预计将在技术进步和加强医疗保健政策的支持下实现强劲增长。为了实现永续的业务成长，公司必须利用创新来提高治疗效果、成本效益和患者的生活质量，同时应对监管复杂性和科学挑战。认识并整合精准医疗和数位健康的趋势可以推动市场进一步扩张和创新。

市场动态：揭示快速发展的自体免疫疾病药物市场的关键市场洞察

供需的动态交互作用正在改变自体免疫疾病治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球自体免疫疾病流行
    • 医疗基础设施快速完善，意识层级不断提高
    • 实验室自动化以促进一些自体免疫诊断测试
  • 市场限制因素
    • 高成本且治疗结果不确定性
  • 市场机会
    • 增加政府机构和非营利组织的资金
    • 自体免疫疾病标靶治疗的出现
  • 市场挑战
    • 自体免疫疾病免疫治疗的副作用

波特五力：驾驭自体免疫疾病药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解自体免疫疾病治疗市场的外部影响

外部宏观环境因素在塑造自体免疫疾病治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解自体免疫疾病治疗药物市场的竞争状况

对自体免疫疾病治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵自体免疫疾病治疗市场供应商的绩效评估

FPNV定位矩阵是评估自体免疫疾病治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为自体免疫疾病治疗药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对自体免疫疾病治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球自体免疫疾病盛行率增加
      • 医疗基础设施的快速改善和病患意识的提高
      • 实验室自动化促进多种自体免疫诊断测试
    • 抑制因素
      • 治疗费用高，治疗效果不确定。
    • 机会
      • 增加政府机构和非营利组织的资金
      • 自体免疫疾病标靶治疗的出现
    • 任务
      • 自体免疫疾病免疫治疗的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自体免疫疾病治疗药物市场：副产品

  • 诊断设备
  • 药物
    • 胺基或5-ASA
    • 蒽甙
    • Avonex
    • Betaseron
    • 卡利泊三烯
    • 科帕松
    • 皮质类固醇
    • 糖皮质激素
    • 羟氯喹
    • 胺基甲基叶酸
    • 非类固醇消炎剂
    • Rebif

第七章自体免疫疾病治疗药物市场：依应用分类

  • 局部自体免疫疾病
  • 系统性自体免疫疾病

第八章北美和南美自体免疫疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区自体免疫疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲自体免疫疾病治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA
Product Code: MRR-030C42D3EDB7

The Autoimmune Disease Therapeutics Market was valued at USD 198.99 billion in 2023, expected to reach USD 214.54 billion in 2024, and is projected to grow at a CAGR of 7.90%, to USD 339.00 billion by 2030.

The Autoimmune Disease Therapeutics market encompasses treatments and pharmaceuticals aimed at managing and mitigating autoimmune disorders, where the body's immune system mistakenly attacks its own tissues. The necessity for these therapeutics is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, demanding advanced medical interventions. Application of these therapeutics ranges from biologics and immunosuppressants to monoclonal antibodies, targeting specific components of the immune system to alleviate symptoms and improve patient outcomes. End-use involves hospitals, clinics, and specialty centers dedicated to managing autoimmune conditions.

KEY MARKET STATISTICS
Base Year [2023] USD 198.99 billion
Estimated Year [2024] USD 214.54 billion
Forecast Year [2030] USD 339.00 billion
CAGR (%) 7.90%

Key growth factors influencing this market include advancements in biotechnology, heightened awareness of autoimmune diseases, and increased investment in R&D for novel treatments. The rise in personalized medicine also propels growth, as therapies can be tailored to individual genetic profiles. Opportunities lie in emerging markets with growing healthcare infrastructure, coupled with the demand for accessible therapies. Collaborations between pharmaceutical companies and research institutions can lead to breakthrough treatments. Companies must focus on enhancing drug efficacy and safety profiles to capture market share.

However, challenges persist, such as high treatment costs, stringent regulatory frameworks, and potential side effects associated with long-term medication use. Limited understanding of disease mechanisms further hinders breakthrough advancements. Innovations should focus on gene therapies and the development of more precise biologics with fewer side effects. Digital health solutions like telemedicine and digital therapeutics can enhance patient monitoring and adherence to treatments.

Overall, the market is dynamic, with robust growth prospects supported by technological advances and healthcare policy enhancements. For sustainable business growth, companies must leverage innovations that improve therapeutic efficacy, cost-effectiveness, and patient quality of life while navigating regulatory complexities and scientific challenges. Recognizing and integrating trends in precision medicine and digital health can catalyze further market expansion and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autoimmune Disease Therapeutics Market

The Autoimmune Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of autoimmune diseases across the globe
    • Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
    • Automation of laboratories to ease several autoimmune diagnostic tests
  • Market Restraints
    • High cost and uncertain outcomes of the treatment
  • Market Opportunities
    • Increasing funding by government associations and non-profit organizations
    • Emergence of target therapies for autoimmune disease
  • Market Challenges
    • Side effects of autoimmune diseases immunotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Autoimmune Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autoimmune Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autoimmune Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autoimmune Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autoimmune Disease Therapeutics Market

A detailed market share analysis in the Autoimmune Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autoimmune Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autoimmune Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autoimmune Disease Therapeutics Market

A strategic analysis of the Autoimmune Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Exagen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnostic Equipment and Drugs. The Drugs is further studied across Aminosalicylates or 5-ASA, Anthralin, Avonex, Betaseron, Calicipotriene, Copaxone, Corticosteriods, Glucocorticoids, Hydroxychloroquine, Methotrexate, Non-steroidal Anti-inflammatory Drugs, and Rebif.
  • Based on Application, market is studied across Localized Autoimmune Diseases and Systemic Autoimmune Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of autoimmune diseases across the globe
      • 5.1.1.2. Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
      • 5.1.1.3. Automation of laboratories to ease several autoimmune diagnostic tests
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and uncertain outcomes of the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding by government associations and non-profit organizations
      • 5.1.3.2. Emergence of target therapies for autoimmune disease
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of autoimmune diseases immunotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostic Equipment
  • 6.3. Drugs
    • 6.3.1. Aminosalicylates or 5-ASA
    • 6.3.2. Anthralin
    • 6.3.3. Avonex
    • 6.3.4. Betaseron
    • 6.3.5. Calicipotriene
    • 6.3.6. Copaxone
    • 6.3.7. Corticosteriods
    • 6.3.8. Glucocorticoids
    • 6.3.9. Hydroxychloroquine
    • 6.3.10. Methotrexate
    • 6.3.11. Non-steroidal Anti-inflammatory Drugs
    • 6.3.12. Rebif

7. Autoimmune Disease Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Localized Autoimmune Diseases
  • 7.3. Systemic Autoimmune Diseases

8. Americas Autoimmune Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Autoimmune Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioAgilytix Labs, LLC
  • 8. bioMerieux S.A.
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Exagen, Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Johnson & Johnson Services, Inc.
  • 15. Lupin Limited
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer, Inc.
  • 19. Sanofi S.A.
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Trinity Biotech PLC
  • 23. UCB S.A.
  • 24. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES OR 5-ASA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTHRALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AVONEX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BETASERON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CALICIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COPAXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REBIF, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 154. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023